Effect of echinomycin and PX-478 on cell survival and expression of BCR-ABL1 and Met in KU812, KU812/IR, KCL-22, and KCL-22/IR cells. (A-D) The cell survival rate after treatment with echinomyacin (A, C) and PX-478 (B, D) or combined treatment with echinomycin or PX-478 and imatinib, as determined by the trypan blue staining assay. Cells were administered with echinomycin, PX-478, or imatinib at concentrations mentioned below for three days. The results are exemplary of five independent experiments. *P < 0.01 vs. untreated KU812 or KU812/IR cells. (E-H) KU812, KU812/IR, KCL-22, and KCL-22/IR cells were treated with 5 nM echinomycin for three days. (E, G) Cell lysates were evaluated by immunoblotting using the antibodies. The content of BCR-ABL1, is normalized to the content of β-actin. The results are exemplary of three independent experiments. *P < 0.01 vs. untreated KU812, KU812/IR, KCL-22, or KCL-22/IR cells. (F, H) Cell lysates were evaluated by immunoblotting using the antibodies. The content of Met, is normalized to the content of β-actin. The results are exemplary of three independent experiments. *P < 0.01 vs. untreated KU812/IR or KCL-22/IR cells.
